125 related articles for article (PubMed ID: 33741856)
1. Utility of 18F-FDG-PET/CT in management and prognostication of treatment naïve late-stage soft tissue sarcomas.
Singh TP; Sharma A; Sharma A; Bakhshi S; Patel C; Pandey AK; Dhamija E; Batra A; Kumar R
Nucl Med Commun; 2021 Jul; 42(7):818-825. PubMed ID: 33741856
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Associations between detectable circulating tumor DNA and tumor glucose uptake measured by
Ottestad AL; Johansen H; Halvorsen TO; Dai HY; Wahl SGF; Emdal EF; Grønberg BH
BMC Cancer; 2023 Jul; 23(1):646. PubMed ID: 37434111
[TBL] [Abstract][Full Text] [Related]
4. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
[TBL] [Abstract][Full Text] [Related]
5.
Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
[TBL] [Abstract][Full Text] [Related]
6. Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer.
Pellegrino S; Fonti R; Mazziotti E; Piccin L; Mozzillo E; Damiano V; Matano E; De Placido S; Del Vecchio S
Ann Nucl Med; 2019 Dec; 33(12):937-944. PubMed ID: 31612416
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
8. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.
Lovinfosse P; Janvary ZL; Coucke P; Jodogne S; Bernard C; Hatt M; Visvikis D; Jansen N; Duysinx B; Hustinx R
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1453-60. PubMed ID: 26830299
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
[TBL] [Abstract][Full Text] [Related]
10. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
[TBL] [Abstract][Full Text] [Related]
11. Does baseline [18F] FDG-PET/CT correlate with tumor staging, response after neoadjuvant chemoradiotherapy, and prognosis in patients with rectal cancer?
Deantonio L; Caroli A; Puta E; Ferrante D; Apicella F; Turri L; Sacchetti G; Brambilla M; Krengli M
Radiat Oncol; 2018 Oct; 13(1):211. PubMed ID: 30359275
[TBL] [Abstract][Full Text] [Related]
12. The Role of 18F-FDG PET/CT on Staging and Prognosis in Patients with Small Cell Lung Cancer.
Zer A; Domachevsky L; Rapson Y; Nidam M; Flex D; Allen AM; Stemmer SM; Groshar D; Bernstine H
Eur Radiol; 2016 Sep; 26(9):3155-61. PubMed ID: 26685851
[TBL] [Abstract][Full Text] [Related]
13. Metabolic imaging in recurrent gliomas: comparative performance of 18F-FDOPA, 18F-fluorocholine and 18F-FDG PET/CT.
Sharma A; Garg A; Singh M; Sharma MC; Gupta S; Kunhiparambath H; Tripathi M; Kale SS; Bal C
Nucl Med Commun; 2024 Feb; 45(2):139-147. PubMed ID: 38095139
[TBL] [Abstract][Full Text] [Related]
14. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma.
Albano D; Bosio G; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):87-96. PubMed ID: 30276438
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of
Li Y; Li Y; Huang Y; Wu X; Yang Z; Wu C; Jiang L
Ann Nucl Med; 2021 Sep; 35(9):1048-1057. PubMed ID: 34101153
[TBL] [Abstract][Full Text] [Related]
16. Differentiation of soft tissue and bone sarcomas from benign lesions utilizing
Chen B; Feng H; Xie J; Li C; Zhang Y; Wang S
BMC Med Imaging; 2020 Jul; 20(1):85. PubMed ID: 32711449
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of volume-based 18F-FDG PET/CT parameters and correlation with PD-L1 expression in patients with surgically resected lung adenocarcinoma.
Wang D; Li Y; Chen X; Li P
Medicine (Baltimore); 2021 Sep; 100(35):e27100. PubMed ID: 34477147
[TBL] [Abstract][Full Text] [Related]
18. Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer.
Miccò M; Vargas HA; Burger IA; Kollmeier MA; Goldman DA; Park KJ; Abu-Rustum NR; Hricak H; Sala E
Eur J Radiol; 2014 Jul; 83(7):1169-1176. PubMed ID: 24767630
[TBL] [Abstract][Full Text] [Related]
19. Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer.
Fasmer KE; Gulati A; Dybvik JA; Ytre-Hauge S; Salvesen Ø; Trovik J; Krakstad C; Haldorsen IS
Eur Radiol; 2020 May; 30(5):2443-2453. PubMed ID: 32034487
[TBL] [Abstract][Full Text] [Related]
20. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy.
Yan H; Wang R; Zhao F; Zhu K; Jiang S; Zhao W; Feng R
Acta Radiol; 2011 Jul; 52(6):646-50. PubMed ID: 21508201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
